82PD - European harmonization study for the immunohistochemical detection of ALK-rearranged NSCLC (on behalf of all 16 participating institutes enrolled in...
|Date||27 March 2014|
|Session||Poster Discussion 1|
|Topics|| Non-Small-Cell Lung Cancer, Metastatic
|Presenter||Maximilian von Laffert|
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
A. Warth1, M. von Laffert2, R. Penzel1, P. Schirmacher3, D. Lenze4, M. Hummel2, M. Dietel2
The reliable identification of ALK-gene rearranged NSCLC is crucial for the treatment with ALK-inhibitors. Even though fluorescence in-situ hybridization (FISH) is regarded as the diagnostic gold standard, studies based on immunohistochemistry (IHC) seem promising. However, such an approach is only applicable if it is validated and standardized for multi-centre use.